Compare prices and buy Syn-Ake from 1 research peptide vendor - also called suppliers or sources. Updated daily.
Dipeptide diaminobutyroyl benzylamide diacetate (CAS 823202-99-9), a synthetic peptide derivative sold as Syn-Ake and designed to mimic waglerin-1, a polypeptide toxin from the temple viper (Tropidolaemus wagleri). Its manufacturer describes it as a reversible antagonist of the muscle-type nicotinic acetylcholine receptor that eases the muscle contraction behind expression lines, a mechanism whose supporting data are the manufacturer's own. Sold as a cosmetic ingredient, it has no FDA approval as a drug.
For research purposes only. Not medical advice.
Syn-Ake is a trade name for dipeptide diaminobutyroyl benzylamide diacetate, and it is not a peptide in the ordinary sense. Two of its three residues, beta-alanine and 2,4-diaminobutyric acid, are not protein amino acids, and the molecule ends in a benzylamide cap rather than a free carboxyl or amide terminus. The patent that claims it, filed by Pentapharm AG of Basel in 2004 and now assigned to DSM Nutritional Products, lists it among its preferred compounds as H-(beta-Ala)-Pro-Dab-NH-benzyl. It is catalogued in the Skin and Cosmetic category because of where it is sold, alongside Argireline and Snap-8, not because of chemical kinship with them.
FDA's substance registry holds it as UNII 38H206R00R with CAS 823202-99-9 as its primary registry number, and records the uncapped molecule as its active moiety. That CAS covers the diacetate salt: PubChem gives C23H37N5O7 and an average mass of about 495.6 for the salt against C19H29N5O3 and about 375.5 for the free base. Acetate is therefore roughly a quarter of the labelled mass, so a milligram of the diacetate carries about three quarters of a milligram of the molecule itself unless a label states a free-base weight.
Pentapharm designed the compound to imitate waglerin-1, a 22-residue peptide from the venom of the temple pit viper Tropidolaemus wagleri. The waglerins arose by de novo evolution inside the prepro region of the snake's C-type natriuretic peptide gene, at a site distinct from the natriuretic peptide itself (Debono, Journal of Molecular Evolution, 2017).
Waglerin-1 is a competitive antagonist of the muscle nicotinic acetylcholine receptor, and its selectivity is unusually narrow. Adult mice lacking the gene for the receptor's epsilon subunit resisted its lethal effect, as did neonatal mice whose end-plates still carry the gamma subunit, while in adult wild-type mice it suppressed the end-plate response to acetylcholine with an IC50 of 50 nanomolar (McArdle, Journal of Pharmacology and Experimental Therapeutics, 1999). It also bound about 2100-fold more tightly to the alpha-epsilon than the alpha-delta interface of the mouse receptor, and about 100-fold more tightly to the mouse alpha-epsilon interface than to the rat or human one (Molles, Journal of Biological Chemistry, 2002).
Published work on the three-residue analog is thin, and the independent studies use it as a reference compound. In a 2024 Korean study it served as the positive control for a new receptor-binding peptide and suppressed the nicotine response of nAChR-expressing TE671 cells only at concentrations in the hundreds of micromolar (Bang, International Journal of Molecular Sciences). A 2024 Turkish paper ran docking and dynamics against matrix metalloproteinases and SIRT1 plus antioxidant and safety assays, all in silico or in vitro (Gok, Journal of Biomolecular Structure and Dynamics).
The one placebo-controlled human study was run and written by the manufacturer. Scientists at DSM Nutritional Products in Kaiseraugst, with two contract partners, split 57 volunteers aged 50 to 65 between placebo and a formulation containing the peptide for four weeks, and reported significantly less wrinkle area and length on the forehead while frowning in the active group (p below 0.05) by image analysis (Campiche, International Journal of Peptide Research and Therapeutics, 2021). A 2020 review quoting the manufacturer's own product page gave a reduction in wrinkle visibility of up to 52 percent after 28 days of application (Errante, Frontiers in Chemistry, 2020). A 2026 clinical paper tested a serum containing the ingredient together with acetyl hexapeptide-8, gluconolactone, niacinamide and laminaria extract, so its results cannot be attributed to this one component (Zhu, International Journal of Cosmetic Science).
FDA classifies a product by its intended use, so a cosmetic ingredient needs no premarket approval while a product marketed to affect the structure or any function of the body is a drug. Checked October 22, 2026, FDA's drug approvals database holds no application with it as an active ingredient, its warning-letter full-text search returns nothing for Syn-Ake, and ClinicalTrials.gov has no record of it under the trade name, the INCI name or waglerin. It is absent from both FDA 503A bulk drug substance nomination category documents, updated September 27, 2024 and May 14, 2026, from the 503B nomination categories, from both tables of FDA's Category 2 safety-risk page read live on October 21, 2026 and in an April 2026 archive capture, and from Pharmacy Compounding Advisory Committee materials through July 2026. A substance registry entry is an identifier, not an approval.
No. Waglerin-1 is a 22-residue peptide isolated from the venom of the temple pit viper Tropidolaemus wagleri, and Syn-Ake is a synthetic three-residue molecule designed to imitate it, built from beta-alanine, proline and 2,4-diaminobutyric acid with a benzylamide cap. Nothing in the product comes from a snake. The published pharmacology of the toxin does not transfer automatically: waglerin-1 is a competitive antagonist of the muscle nicotinic acetylcholine receptor with a strong preference for the adult receptor's epsilon subunit, and it binds the human receptor roughly 100-fold less tightly than the mouse one.
Once, in a study its manufacturer ran and authored. Scientists at DSM Nutritional Products in Kaiseraugst, with two contract partners, split 57 volunteers aged 50 to 65 between placebo and a formulation containing the peptide for four weeks and reported significantly less wrinkle area and length on the forehead while frowning in the active group, at p below 0.05 by image analysis, in the International Journal of Peptide Research and Therapeutics in 2021. The widely quoted figure of up to 52 percent lower wrinkle visibility after 28 days comes from the manufacturer's product page as quoted in a 2020 review. Other clinical papers that name the ingredient tested multi-ingredient serums, so their results cannot be attributed to it, and ClinicalTrials.gov holds no record of it as of October 22, 2026.
That depends on what a product claims. FDA classifies a product by its intended use, so a cosmetic ingredient needs no premarket approval, while a product marketed to affect the structure or any function of the body is regulated as a drug regardless of its ingredients. As of October 22, 2026 FDA's drug approvals database lists no application with it as an active ingredient, its warning-letter search returns nothing for Syn-Ake, and the compound appears in neither FDA bulk drug substance nomination category document for compounding nor either table of the Category 2 safety-risk page. It does have an FDA substance registry entry, UNII 38H206R00R, which is an identifier rather than an approval.
The INCI name counts the two-residue part before the capped residue, which is why a molecule of three residues is called a dipeptide. Its registry entry reads dipeptide diaminobutyroyl benzylamide diacetate, with CAS 823202-99-9 and UNII 38H206R00R, and the structure in the originating patent is H-(beta-Ala)-Pro-Dab-NH-benzyl. Cosmetic reviews also print tripeptide-3 and diacetyl tripeptide-3 for it, which are not the names in that registry entry, so a label using them needs the CAS number or the structure to confirm what is in the container.
PeptideScouter computes a price per milligram only for listings sold as vials and labelled in milligrams. The Syn-Ake listings it indexes are bulk raw powder sold by weight rather than vials, so they appear with a price but on no per-milligram comparison on the site. The weight on such a listing also refers to the diacetate salt, which is about a quarter acetate by mass.
Syn-Ake is sold by 1 research peptide vendor indexed on PeptideScouter, with 1 tracked listing compared per vendor in the table above. Pricing is normalized and refreshed daily.
Syn-Ake is currently out of stock across all 1 tracked vendor. The comparison table shows last-seen pricing for reference, and stock state is refreshed daily.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 1 vendor listing Syn-Ake publish a PeptideScouter code, worth 15% off. These listings do not carry a comparable per-milligram price, so code availability is shown without a normalized effective price. Each vendor's code is shown beside its price in the table above.
1 research peptide vendor currently lists Syn-Ake on PeptideScouter. We track 1 listing across size and kit variants.
Syn-Ake's CAS Registry Number is 823202-99-9.
